retatrutide and tirzepatide taken together Switching from to retatrutide: the complete transition guide Retatrutide vs Tirzepatide: Key Differences

H., Karpiel, A

As an unapproved investigational substance, retatrutide could still be argued under S0 (non-approved substances) for tested athletes, so treat it as risky if you compete

It is not merely another version of an existing GLP-1 medicine

Log in Metabolic Daily Pendulum 30 capsules $N/A (MSRP) Already have an account

You can also refer to the How to use NovoLog section below

Key Takeaways Mazdutide is a dual GLP-1/glucagon agonist: Developed by Innovent Biologics, it activates GLP-1 and glucagon receptors but NOT GIP Tirzepatide is a dual GLP-1/GIP agonist: FDA-approved compound activating different second receptor than Mazdutide Retatrutide is a triple agonist: Activates all three receptors (GLP-1, GIP, and glucagon) for most comprehensive coverage Glucagon receptor activation distinguishes Mazdutide: Different metabolic pathway from Tirzepatide despite both being "dual agonists" Regulatory status differs: Tirzepatide is FDA-approved